Organon & Co (OGN)
Debt-to-capital ratio
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Total stockholders’ equity | US$ in thousands | 472,000 | 493,000 | 144,000 | 48,000 | -70,000 | -589,000 | -555,000 | -737,000 | -892,000 | -1,066,000 | -1,137,000 | -1,250,000 | -1,508,000 | -1,618,000 | -1,934,000 | 4,722,000 | -820,000 |
Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | 0.00 | — |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $472,000K)
= 0.00
The debt-to-capital ratio for Organon & Co has remained consistently at 0.00% from March 31, 2021, to December 31, 2024, indicating that the company has not utilized debt to fund its operations or investments during this period. A debt-to-capital ratio of 0.00% suggests that the company's capital structure is primarily composed of equity rather than debt. This may indicate a conservative approach to financing, as the company is not relying on borrowed funds to support its business activities.
Peer comparison
Dec 31, 2024
Company name
Symbol
Debt-to-capital ratio
Organon & Co
OGN
0.00
Abbott Laboratories
ABT
0.00
AbbVie Inc
ABBV
0.00
ACADIA Pharmaceuticals Inc
ACAD
0.00
Alkermes Plc
ALKS
0.00
Amphastar P
AMPH
0.46
ANI Pharmaceuticals Inc
ANIP
0.00
Arcus Biosciences Inc
RCUS
0.00
Biomarin Pharmaceutical Inc
BMRN
0.10
Bristol-Myers Squibb Company
BMY
0.74
Catalyst Pharmaceuticals Inc
CPRX
0.00